Lataa...
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer
Small cell lung cancer (SCLC), which accounts for 10%–15% of lung cancer cases, is an aggressive disease characterized by rapid growth and early widespread metastasis. Although up to 80% of patients respond to first-line chemotherapy, most eventually relapse, and there are no approved agents beyond...
Tallennettuna:
| Julkaisussa: | Oncologist |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
AlphaMed Press
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4978554/ https://ncbi.nlm.nih.gov/pubmed/27354668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0523 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|